Shedding Light on Triple Negative Breast Cancer
Could blocking a testosterone receptor lead to a new way of treating an aggressive form of breast cancer? Researchers at Mayo Clinic in Arizona and The Translational Genomics Research Institute (TGen) are exploring this very question.
Preliminary results of the Mayo Clinic-TGen collaborative study show that the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).
TNBC is highly aggressive and affects approximately 10 to 20 percent of breast cancer patients. The disease is characterized by larger, faster-growing tumors than other types of breast cancer and has limited treatment options.
Click here for entire news release.
Soundbites from lead researcher, Barbara Pockaj, M.D., are available in the downloads above.
Expert title: Barbara Pockaj, M.D., Mayo Clinic Surgical Oncologist